

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Final Appraisal Determination

NB: no ACD was issued

- | |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

During the scoping process some consultees raised the issue of age, specifically that the population defined in the scope should not be restricted to the current licensed indication (adults aged 18-80 years) and that adults aged 80 years and over should be considered.

- | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">• NICE can only appraise alteplase for the treatment of acute ischaemic stroke for the population indicated in its UK marketing authorisation. Therefore, the issue raised cannot be addressed within the appraisal and no changes were made to the draft scope. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

- | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

In its submission the manufacturer stated that the incidence and outcome of stroke varies according to race, sex, social class and geographical location.

- | |
|----------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none">• The issue raised reflects the epidemiology of stroke and is not an |
|----------------------------------------------------------------------------------------------------------------------|

equality issue that could be addressed by NICE technology appraisal guidance.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

The Committee was aware that extension of the licence to 4.5 hours after symptom onset may enable increased access to treatment with alteplase for patients in remote or rural locations. This is noted by the Committee in section 4.10 of the FAD.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, see section 4.10 and FAD Summary Table.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 24 07 12